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Abstract:  Background: Patients with the human immunodeficiency virus (HIV) are at risk for multiple pulmonary 
complications including pulmonary hypertension. Exercise induced pulmonary hypertension (EIPH) has been previously 
described in patients with scleroderma, sickle cell disease and chronic obstructive pulmonary disease, yet has not been 
associated with the HIV population. 
Methods: A prospective case-control study design was implemented. Four HIV patients with unexplained dyspnea and 
four healthy controls underwent symptom-limited stationary bicycle exercise. Transthoracic Doppler Echocardiography was 
used to measure tricuspid regurgitation velocity which was used to calculate the right ventricular to right atrial pressure 
(RV-RA) gradient at rest and at peak exercise using the simplified Bernoulli’s equation. Change in RV-RA gradient 
between rest and peak exercise was calculated and considered to represent change in pulmonary arterial systolic pressure.  
Results: The mean age was 41.25 years (±8.7) for patients and 33.5 years (±6.0) for controls. The mean CD4 count of 
patients was 191.5 cells/μL (±136.2). Patients had a significantly higher increase in RV-RA gradient as compared to 
controls (180.2% vs. 27.5%, p = 0.03).  
Discussion: This pilot study suggests that it is feasible to use recumbent bicycle and transthoracic Doppler 
echocardiography for the evaluation of EIPH among HIV patients with dyspnea of unknown etiology. The study is too 
small to draw any broad conclusion. Further evaluation of this concept with a larger study is warranted.  
Keywords: Human immunodeficiency virus (HIV), pulmonary hypertension, exercises induced pulmonary hypertension. 
BACKGROUND 
  Patients with the human immunodeficiency virus (HIV) 
are at risk for multiple pulmonary complications including 
infection, malignancy, interstitial lung disease, and 
pulmonary hypertension (PH). The pathogenesis of HIV-
associated PH is multifactorial and poorly understood. 
Plexogenic pulmonary arteriopathy is the most common 
lesion identified, reflective of medial hypertrophy with 
concentric intimal endothelial proliferation [1-4]. The HIV 
virus or its related proteins are not present in the vascular 
endothelium as confirmed using electron microscopy,   
 
 
*Address correspondence to this author at the Rush University Medical 
Center, Section of Cardiology, 1653 W. Congress Pkwy, Chicago, IL 60612, 
Tel: 312-563-2534; Fax: 312-942-6334;  
E-mail: rami_doukky@rush.edu 
immunohistochemistry, polymerase chain reaction, and 
DNA in situ hybridization [5-7]. HIV-associated PH has 
been estimated to occur in 1/200 (0.5%) of HIV infected 
individuals [1] and when associated with worsening World 
Health Organization (WHO) functional class is an 
independent predictor of death associated with right heart 
failure and sudden cardiac death [3, 7]. 
  Exercise-induced pulmonary hypertension (EIPH) has 
been described in patients with scleroderma [8], sickle cell 
disease [9], and chronic obstructive pulmonary disease [10].
 
Some scleroderma patients with EIPH progress to resting 
PH, which suggests that EIPH may be an early marker of PH 
at rest [9, 11]. PH at rest is well recognized in HIV, yet the 
phenomenon of EIPH has not been described in this 
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  Unexplained exertional dyspnea is not uncommon among 
HIV patients. Unfortunately, in some patients no final 
diagnosis is made despite exhaustive evaluations including 
searches for pulmonary, cardiovascular, infectious, and 
malignant etiologies. We believe that unexplained exertional 
dyspnea in the HIV population may be a clinical presentation 
of EIPH. By identifying these patients early in their disease, 
therapeutic strategies to improve immune status with highly 
active anti-retroviral therapy (HAART) or treatment with 
pulmonary vasodilators may be initiated and have beneficial 
effects on quality of life and potentially mortality. We 
hypothesize that there is a population of HIV patients with 
exercise-induced PH, similar to other patient groups with 
secondary causes of PH.  
METHODS 
 A prospective case-control study design was 
implemented. Patients with HIV and unexplained dyspnea 
(cases) were recruited from an academic medical center, a 
large urban county hospital, and an outpatient HIV center 
from November 2005 to May 2007. The control subjects 
were four healthy young volunteers. Inclusion criteria for   
the cases were HIV patients with unexplained exertional 
dyspnea and normal chest imaging. Patients were excluded  
if they had other secondary forms of PH including 
thromboembolic disease, other forms of cardiac or valvular 
dysfunction, autoimmune diseases, severe obstructive sleep 
apnea, sarcoidosis, sickle cell disease, hyperthyroidism, use 
of appetite suppressant drugs, or liver cirrhosis. Patients 
were also excluded if they were pregnant or less than 18 
years of age. Patients’ functional status was classified 
according to the New York Heart Association (NYHA) 
classification. All patients underwent a thorough clinical 
evaluation of dyspnea by one of the clinical investigators in 
addition to complete pulmonary function testing. Lung 
volumes, diffusing capacity, and flow rates were measured 
using standard American Thoracic Society and European 
Respiratory Society guidelines [12]. Patients were excluded 
if they were identified to have an alternate cause for dyspnea 
such as obstructive or restrictive lung disease, abnormal 
diffusing capacity suggestive of thromboembolic disease   
or interstitial lung disease or markedly abnormal chest 
imaging. Consequently, eligible patients underwent a 
complete resting transthoracic echocardiogram. The 
following echocardiographic abnormalities would result in 
exclusion from the study: impaired left ventricular systolic or 
diastolic function, regional wall motion abnormalities, 
evidence suggestive of elevated left ventricular filling 
pressure [13], right ventricular dysfunction, more than mild 
valvular heart disease, any degree of pulmonic valve 
stenosis, absence of tricuspid regurgitation or baseline 
elevated systolic pulmonary artery pressures.  
  Eligible patients and controls exercised on a recumbent 
bicycle ergometer. The patients were connected to a 
continuous electrocardiogram (ECG) monitor. The blood 
pressure and heart rate were measured at rest and during 
exercise. Symptoms of dyspnea were recorded using the 
Borg Dyspnea Scale. During exercise symptoms, vital signs, 
and workload achieved were recorded. Exercise was started 
at an initial work load of 25 Watts and gradually increased 
every 3 minutes. Subjects were encouraged to exercise   
to maximum capacity. The exercise was terminated   
if the subject complained of symptoms (chest pain, 
worsening dyspnea, or leg fatigue), ischemic ECG changes, 
dysrhythmias, hypertension (>220/110 mmHg) or 
hypotension (>10 mmHg from baseline). Both at rest and at 
peak-exercise, tricuspid regurgitation jet velocity (TRV) was 
interrogated using color and continuous-wave Doppler in   
the following standard views: parasternal right ventricular 
inflow, parasternal short axis, apical four-chamber, and 
subcostal (Fig. 1). In all cases, agitated saline was injected to 
enhance the Doppler signals. The highest TRV was used to 
calculate the pressure-gradient between the right ventricle 
and the right atrium (RV-RA) using the simplified Bernoulli 
 
Fig. (1). Peak tricuspid regurgitation jet velocity at rest (A) and at peak exercise (B). 46    The Open Cardiovascular Medicine Journal, 2012, Volume 6  Doukky et al. 
equation [RV-RA gradient = 4  TRV
2] [14] (Fig. 1). The 
right atrial pressure (RAP) was estimated from inferior   
vena cava size and collapsibility during inspiration [15]. The 
pulmonary arterial systolic pressure (PASP) was calculated 
at rest and peak-exercise from the sum of RV-RA gradient 
and estimated RAP [PASP = 4 TRV
2 + RAP] [14]. 
  Independent samples two-tailed Student’s T-test was 
used to compare percent change in means of RA-RV 
pressure gradient in response to exercise. Data analysis was 
performed using SPSS version 18.0 (Chicago, IL). The study 
was approved by the Rush University Medical Center and 
John H. Stroger, Jr. Hospital of Cook County Institutional 
Review Boards. 
RESULTS 
  Eight patients were initially evaluated for symptoms   
of exertional dyspnea. All were WHO functional class II   
or III. Two patients were excluded, one with diffuse 
lymphadenopathy identified on chest computed tomography 
which was suggestive of malignancy, and another patient 
was lost to follow-up. Six patients were further evaluated. 
One patient met all inclusion criteria including no evidence 
of primary lung disease, no coronary ischemia, and normal 
resting echocardiogram; however was lost to follow-up   
and never underwent an exercise study. Patient 5 (Table 1) 
had normal chest imaging, normal pulmonary function 
studies, no evidence of coronary ischemia, an unremarkable 
cardiopulmonary exercise test, and a normal resting 
echocardiogram. However peak-exercise TRV could not be 
identified (despite contrast enhancement) and therefore his 
data is not included in the analysis. The remaining four 
patients are included in final data analysis. 
  The four patients (2 women and 2 men) who were 
included in the analysis had a mean age of 41.25 years (±8.7) 
and a mean CD4 count of 191.5 cells/μL (±136.2) (Table 1). 
The mean age of controls was 33.5 years (±6.0). Patients 
exercised on a recumbent bicycle to a mean Borg Dyspnea 
score of 3.8; which correlates with moderate to severe 
impairment. Among HIV patients, the mean resting RV-RA 
gradient was 6.4 mmHg (±5.4) and the mean peak-exercise 
RV-RA gradient was 15.8 mmHg (±11.2). Among controls, 
the mean resting RV-RA gradient was 20.0 (±7.2) mmHg 
and the mean RV-RA gradient at peak-exercise was 25.3 
(±8.5) mmHg. In all cases and controls the TRV, the RV-RA 
gradient and the PASP increased with exercise. The absolute 
increase in mean RV-RA gradient among patients was 9.4 
(±6.3) mmHg compared to 5.3 (±1.6) mmHg among 
controls; a statistically insignificant difference (p= 0.25). 
However, the percentage change in RV-RA gradient relative 
to baseline among cases was +180.2% (±110.2), compared to 
+27.5% (±8.3) among controls; a statistically significant 
difference (p= 0.03) (Table 2). Similarly, the percentage 
increase in the calculated PASP relative to baseline among 
cases was 55.3% (±24.8), compared to 21.5% (±5.7) among 
controls; a statistically significant difference (p = 0.04) 
(Table 2).  
DISCUSSION 
  We detail the first description of HIV patients with 
exercise-induced increase in Doppler-measured pulmonary 
Table 1.  Clinical Characteristics of HIV Patients with Exertional Dyspnea 
 Age  Gender 
Race 
Symptoms  
 
NYHA 
Classification 
CD4 count 
(cells/mm
3) 
HIV RNA Viral Load 
(mm/C3) 
Chest 
Imaging 
HAART 
Therapy 
1  32, Man 
African American 
Dyspnea 
3 months 
Class III  <5  > 100,000  Normal  No 
2  37, Man 
Hispanic 
Dyspnea 
12 months 
Class III  183  Undetectable  Normal  Yes 
3  52, Woman 
African American 
Dyspnea 
6 months 
Class III  284  Undetectable  Normal  Yes 
4  44, Woman 
Hispanic 
Dyspnea 
2years 
Class III  297  2890  Small Cysts  No 
5  39, Man 
African American 
Dyspnea 
2years 
Class III  186  83  Normal  Yes 
 
Table 2.  Results 
 Cases  (n=4) Controls  (n=4)  p value 
Change in RV-RA gradient  9.4 (±6.3) mmHg  5.3 (±1.7) mmHg  0.25 
Percent increase in RV-RA gradient  180.2% (±110.22)  27.5% (±8.3)  0.03 
Percent change in PASP  55.3% (±24.8)  21.5% (±5.7)  0.04 
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pressure in excess to that observed in healthy volunteers. 
This phenomenon has previously been reported in patients 
with scleroderma, sickle cell disease, and COPD, but to   
our knowledge, has not yet been described in the HIV 
population. In our patients, alternative causes of dyspnea 
were thoroughly evaluated including opportunistic infections, 
underlying pulmonary or cardiovascular diseases, or 
thromboembolism. Our research suggests that exercise 
echocardiography searching for EIPH should be considered 
in the clinical evaluation of unexplained dyspnea in the HIV 
patient.  
  Pulmonary hypertension is increasingly recognized as a 
complication of HIV leading to worsening mortality. Patients 
with HIV-associated PH have a median survival of 1.3 years 
which is worse than the 2.6 year survival reported in primary 
pulmonary hypertension patients [16]. Furthermore, the 
median time interval between diagnosis of HIV related PH 
and death is only 6 months [3]. Therefore, identification of 
these patients during early stages of the disease may lead to 
initiation of therapy which has the potential to modify 
symptoms and possibly mortality. 
  Measurement of tricuspid regurgitation jet velocity by 
echocardiography is generally reliable in detecting both 
resting and exercise PH [10, 17, 18]. The advantage of 
echocardiography is its noninvasive nature, reproducibility 
and favorable correlation to invasive measurement techniques 
[19, 20]. Furthermore, echocardiography is useful in 
excluding other causes of elevated right-sided pressures such 
as valvular or congenital heart disease [21]. However, when 
evaluating a patient with exertional dyspnea, the resting 
pulmonary pressure does not reflect exercise hemodynamics. 
During exercise, there normally is an increase in stroke 
volume, relatively small increases in pulmonary artery 
pressures, yet an overall decrease in pulmonary vascular 
resistance [19]. Nonetheless, scleroderma patients with EIPH 
typically show increases in pulmonary artery systolic 
pressures, reflective of increased vascular resistance during 
exercise [8]. Doppler echocardiography, therefore, is reliable 
in distinguishing pathologic from physiologic responses to 
exercise and has been utilized to identify EIPH in both the 
recumbent and supine position [8, 17, 18]. In our study, we 
applied the Bernoulli equation on the measured tricuspid 
regurgitant velocity to calculate the RV-RA gradient at rest 
and peak-exercise. Assuming that the right atrial pressure is 
constant, any change in the RV-RA gradient between the 
resting state and peak-exercise reflects equal change in the 
pulmonary arterial systolic pressure.  
  We also found that the patient with the highest increase 
in RV-RA gradient was the patient with the lowest CD4+ T-
lymphocyte count. The other 3 patients had average CD4+ 
T-lymphocyte counts greater than 200 cells/mm
3. The role 
that the degree of immunodeficiency and viral load have on 
the development of HIV-associated PH is conflicting [22]. In 
one retrospective study, initiation of HAART therapy alone 
resulted in significant regression of RV-RA gradient 
suggesting that HIV may trigger mechanisms leading to 
increases in pulmonary vascular resistance [23, 24]. Nunes
7 
showed that patients receiving combination antiretroviral 
therapy and a CD4 count greater than 212 cells/mm
3 had an 
improved mortality. However, other investigators note the 
lack of correlation between the development of PH in HIV 
individuals and their level of immunodeficiency or CD4+ T-
lymphocyte counts [16, 25]. HIV related PH can occur early 
and in late stages of HIV infection and does not always seem 
related to degree of immunodeficiency [26]. Therefore in   
any HIV patient with unexplained dyspnea a clinical 
investigation for PH is warranted, regardless of the immune 
status.  
  Other therapeutic strategies for HIV related PH may 
include vasodilator treatment such as prostacyclin analogues, 
endothelin antagonists or phosphodiesterase inhibitors. 
These agents are typically reserved for more severe WHO 
Class III or IV patients. The use of intravenous epoprostenol 
in patients with HIV-associated PH has shown favorable 
improvements in hemodynamic parameters; decreases in 
pulmonary artery pressures and pulmonary vascular 
resistance, increase in cardiac index, and improved clinical 
and exercise status [7, 16, 27]. The risks of chronic 
intravenous epoprostenol therapy requiring central line 
placement and the potential for catheter related blood stream 
infections may preclude use of continuous infusion in these 
patients. Other therapies include targeting endothelin-1, a 
potent vasoconstrictor and important component of the 
pathogenesis of HIV-associated PH. This highlights the 
benefits of endothelin antagonists such as bosentan and 
ambrisentan [28, 29]. Finally, the ease with which oral 
phosphodiesterase inhibitors can be administered may   
also lead to promising treatment strategies [30-32]. As far as 
HIV-associated PH or EIPH, there have been no studies 
evaluating the use of pulmonary artery vasodilators, yet we 
can only hypothesize that clinical treatment may improve 
WHO functional class or 6-minute walk distance.  
Limitations  
  There are several limitations to our study. First, the 
number of patients and controls studied is small. It was 
challenging to identify subjects with HIV and unexplained 
dyspnea who met all the enrollment criteria. Secondly   
our investigation lacks confirmation by right-heart 
catheterization, which remains the best diagnostic tool to 
assess pulmonary hemodynamics. However, it is difficult to 
enroll patients in an investigation that involves such invasive 
testing. Therefore, we felt that measurement of TRV by 
Doppler-echocardiography is noninvasive and reliable and 
has been a useful research tool in a number of previous 
studies. Thirdly, acquiring a “perfect” tricuspid regurgitation 
Doppler signal with a clearly identifiable peak-velocity 
while the patient is actively engaged in bicycle exercise was 
particularly challenging. This was most problematic in three 
of the four patients enrolled. It seems that this has not been a 
problem for the control subjects enrolled later in the   
study, as our echocardiography technologist became more 
comfortable with acquisition. When the peak TRV was not 
clearly identifiable we recorded the highest discernable 
velocity which may not reflect peak TRV in those subjects. 
This problem questions, to some extent, the validity and 
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standardizing the mode of exercise and patient position 
during Doppler-echocardiography acquisition in the detection 
of EIPH. Finally, long term follow-up was not established 
and therefore progression to resting PH is purely 
hypothetical. Larger studies with confirmation by right-heart 
catheterization and long-term follow-up may best clarify the 
pathophysiology and clinical characteristics of EIPH in the 
HIV population.  
CONCLUSION 
  We describe the first report of four HIV patients with 
exercise induced dyspnea without evidence of PH at rest,   
yet with manifestations of exercise-induced increase in 
pulmonary systolic pressure. EIPH may be an early marker 
for HIV-associated PH or purely exist as an exercise induced 
phenomenon. Our preliminary data is limited by a small 
sample size, yet may lead to larger investigations of this 
novel disease process. If identified, both cause and treatment 
need to be further investigated as there still remains clinical 
uncertainty regarding the prevalence of HIV-associated 
EIPH and the progression of the disease. By establishing an 
early and accurate diagnosis, HIV patients can be targeted 
for careful follow-up and potential treatment to lower 
pulmonary artery pressures, although further studies are 
warranted to address this issue. Finally, since HLA-DR6 and 
DR52 have been associated in the pathogenesis of HIV-
associated PH [33], genetic analysis using single nucleotide 
polymorphisms may identify candidate genes involved in the 
development of EIPH.  
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